Rationale and Design of LAPLACE‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy

This study will also provide comparative efficacy, safety, and tolerability data between evolocumab and ezetimibe when added to background atorvastatin therapy.
Source: Clinical Cardiology - Category: Cardiology Authors: Tags: Trial Designs Source Type: research

Related Links:

Authors: Ponticelli C, Arnaboldi L, Moroni G, Corsini A Abstract Introduction: Lipid disorders are frequent after kidney transplantation (KT) and KT recipients are considered at high- or very-high cardiovascular risk. Among many concurring factors, a major role is played by immunosuppressants.Areas covered: General measures to manage lipid disorders first include physical activity and diet counseling. Modulating the doses of immunosuppressants also improves dyslipidemia. When lipid-lowering drugs are necessary to control elevated plasma cholesterol and/or triglycerides, statins are the cornerstone for managing hype...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Should you get a mammogram at age 45? Should you start taking a statin? Is now the time to get a hip replacement? You can go down rabbit holes trying to research these online, talk to friends about their experiences, or have a few too many opinions thrown at you in online communities. And when […]
Source: EMR and HIPAA - Category: Information Technology Authors: Tags: Ambulatory Clinical Communication and Patient Experience Healthcare IT Hospital - Health System LTPAC Chronic Care Disease Management Source Type: blogs
Publication date: Available online 18 February 2020Source: Journal of the Formosan Medical AssociationAuthor(s): Fang-Ju Lin, Kou-Gi Shyu, I-Chang Hsieh, Wayne Huey-Herng Sheu, Shih-Te Tu, Shoou-Jeng Yeh, Chin-I Chen, Kuo-Cheng Lu, Chia-Chao Wu, Wen-Yi Shau, Timothy J. Inocencio, Yao-Chun Wen, Hung-I YehBackgroundThe recommended target low-density lipoprotein cholesterol (LDL-C) level for coronary artery disease (CAD) patients has been lowered from 100 to 70 mg/dL in several clinical guidelines for secondary prevention. We aimed to assess whether initiating statin treatment in CAD patients with baseline LDL-C 70&ndash...
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
Publication date: Available online 19 February 2020Source: Pharmacological ResearchAuthor(s): Niki Katsiki, Dimitri P. Mikhailidis, Gani Bajraktari, Andre R. Miserez, Arrigo F.G. Cicero, Eric Bruckert, Maria-Corina Serban, Erkin Mirrakhimov, Fahad Alnouri, Željko Reiner, György Paragh, Amirhossein Sahebkar, Maciej Banach, on behalf of the International Lipid Expert Panel (ILEP)
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
AbstractPatients with rheumatoid arthritis (RA) suffer from a magnitude of excess cardiovascular risk. A paradoxical lipid pattern has been observed in rheumatoid arthritis patients where low levels of total cholesterol and low-density lipoprotein are associated with a higher risk of cardiovascular disease. This paper aims to break down the evidence explaining why patients with low to normal LDL, and total cholesterol have such excess cardiovascular risk. A component of the enhanced cardiovascular risk is systemic inflammation and the subsequent pro-atherogenic dyslipidemia patterns. Due to this “lipid paradox,&rdquo...
Source: Journal of Cardiovascular Translational Research - Category: Cardiology Source Type: research
CONCLUSIONS: Adipocytokines are a predictive factor of peritoneal function and the duration of PD in patients undergoing PD. PMID: 32063216 [PubMed - as supplied by publisher]
Source: Peritoneal Dialysis International - Category: Urology & Nephrology Tags: Perit Dial Int Source Type: research
AbstractMany obese patients are exposed to hypolipidemic and serotonin ‐norepinephrine reuptake inhibitor (SNRI) drugs. Statins are one of the most marketed drugs in the world to treat dyslipidemia, while sibutramine, a SNRI drug, is prescribed in some countries to treat obesity and is detected as an additive in many adulterated weight loss supplements marketed world wide. Previous studies reported adverse effects of isolated exposure to these drugs on male rat reproductive parameters. In the present work, we further investigated male reproductive toxicity of these drugs, administered in isolation or combination in adult...
Source: Journal of Applied Toxicology - Category: Toxicology Authors: Tags: RESEARCH ARTICLE Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Conclusions and Implications for Cancer SurvivorsMore than one-third of cancer survivors were statin-eligible but untreated under current guidelines. There is room for improvement to reduce the burden of non-cancer mortality by managing traditional cardiovascular risk factors.
Source: Journal of Cancer Survivorship - Category: Cancer & Oncology Source Type: research
Better understanding needed to stave off overdose deaths, warns HSIB Related items fromOnMedica Withdrawn valsartan meds not linked to short-term cancer risk Too few women take part in many CVD clinical trials Pharmacists could offer high-dose statins direct to patients Cannabinoids not recommended to treat cancer-related pain GPs defend practice on prescribing statins
Source: OnMedica Latest News - Category: UK Health Source Type: news
More News: Atorvastatin Calcium | Cardiology | Cardiovascular | Cholesterol | Clinical Trials | Eyes | Heart | Lipitor | Statin Therapy | Study | Vytorin | Zetia | Zivast